VERICEL CORPORATION Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value
VERICEL CORPORATION (VCEL) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value of $17.71 per share for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-07-30.
Financial Statements › Notes › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue · last filed 2026-07-30
- VERICEL CORPORATION share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for the quarter ending 2026-06-30 was $17.71, a 17.70% decline year-over-year.
- VERICEL CORPORATION share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for the quarter ending 2026-03-31 was $19.92, a 33.44% decline year-over-year.
- VERICEL CORPORATION share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for the quarter ending 2025-09-30 was $17.74, a 36.03% decline year-over-year.
- VERICEL CORPORATION share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for the quarter ending 2025-06-30 was $21.52, a 22.73% decline year-over-year.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 9 month |
|---|---|---|---|
| 2026-06-30 | $17.71 10-Q · filed 2026-07-30 | $19.71 10-Q · filed 2026-07-30 | |
| 2026-03-31 | $19.92 10-Q · filed 2026-05-07 | ||
| 2025-09-30 | $17.74 10-Q · filed 2025-11-06 | $28.59 10-Q · filed 2025-11-06 | |
| 2025-06-30 | $21.52 10-Q · filed 2026-07-30 | $28.84 10-Q · filed 2026-07-30 | |
| 2025-03-31 | $29.93 10-Q · filed 2026-05-07 | ||
| 2024-09-30 | $27.73 10-Q · filed 2025-11-06 | $28.08 10-Q · filed 2025-11-06 | |
| 2024-06-30 | $27.85 10-Q · filed 2025-07-31 | $28.14 10-Q · filed 2025-07-31 | |
| 2024-03-31 | $28.21 10-Q · filed 2025-05-08 | ||
| 2023-09-30 | $22.36 10-Q · filed 2024-11-07 | $18.80 10-Q · filed 2024-11-07 | |
| 2023-06-30 | $19.30 10-Q · filed 2024-08-01 | $18.41 10-Q · filed 2024-08-01 | |
| 2023-03-31 | $18.00 10-Q · filed 2024-05-08 | ||
| 2022-09-30 | $15.58 10-Q · filed 2023-11-08 | $20.55 10-Q · filed 2023-11-08 | |
| 2022-06-30 | $19.25 10-Q · filed 2023-08-02 | $20.74 10-Q · filed 2023-08-02 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| BIOCRYST PHARMACEUTICALS INC (BCRX) | United States | $2.175B | -6.63 |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| Greenland Mines Ltd (GRML) | United States | $2.362B | |
| Immunocore Holdings plc (IMCR) | $1.613B | -90.43 | |
| Taysha Gene Therapies, Inc. (TSHA) | United States | $1.564B | -14.80 |